Intervention study about the additive infusion of concentrated fibrinogen preparation and the amount of blood transfusion for the massive hemorrhage case

Intervention study about the additive infusion of concentrated fibrinogen preparation and the amount of blood transfusion for the massive hemorrhage case - Intervention study about the additive infusion of concentrated fibrinogen preparation and the amount of blood transfusion for the massive hemorrhage case

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019027

Enrollment

Registered

2015-09-15

Start date

2014-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Massive hemorrhage by trauma, gastrointestinal hemorrhage

Interventions

Term:28 weeks infusion:Red cell concentrated 10units, ordinary blood transfusion concentrated fibrin preparation 3g Term:28 weeks infusion:Red cell concentrated 10units, ordinary blood transfusion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.The man and woman who are 20 years or older. 2.The patients that doctor recognizes necessity of massive blood transfusin by MTP due to massive hemorrhage by injury and gastrointestinal bleeding. 3.The patients who are conveyed and admitted to emergency and critical care center, without tranferring to the other hospital and Obstetrics, heart blood vessel sugeryy patient

Exclusion criteria

Exclusion criteria: 1.Pregnant woman 2.Under 20 years old 3.Immunocompromised (state) patients 4.Patients with allegy for blood products 5.Patients who are diagnosed as congenital low fibrinogen blood symptom 6.the patient that informed consent is not provided 7.the patient who is dead during primary care treatment even MTP procedure was exercised or not given the treatment with RCC,FFP and the concentrated fibrin preparation. 8.the patient who cannot perform a blood test after dosage

Design outcomes

Primary

Measure	Time frame
The amount of total blood tranfusion until hemostasis completion	—

Countries

Japan

Contacts

Public ContactKiyoshi Murata

Medical Hospital,Tokyo Medical and Dental University Trauma and Acute Critical Care Medical Center

murata.acc@tmd.ac.jp03-3813-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026